Angioimmunoblastic T-Cell Lymphoma (AITL)
Overview
Angioimmunoblastic T-Cell Lymphoma is a Mature T and NK Neoplasm (parent MTNN) and a subtype of peripheral T-cell lymphoma.
Cohorts in the corpus
- mtnn_msk_2022: AITL was the most common histology in the 132-patient nodal PTCL cohort at MSK (47%) PMID:37078708.
Recurrent alterations
- RHOA: 88% of RHOA mutations in AITL were the canonical G17V variant PMID:37078708.
- TET2, DNMT3A, IDH2: frequently mutated across the PTCL cohort that is 47% AITL PMID:37078708.
- TP53 mutations and 17p deletions were the only somatic aberrancies independently correlated with inferior PFS on CHOP-based therapy in the PTCL cohort PMID:37078708.
- RHOA G17V dominant-negative mutation is present in ~67% of AITL cases, abolishes GTP binding, and is functionally characterised as loss-of-function in a yeast complementation model PMID:24816253
Subtypes
- AITL analyzed alongside PTCL-NOS, PTCL-TFH, ALK+/− ALCL within the nodal PTCL cohort PMID:37078708.
Therapeutic landscape
- Curative-intent CHOP-based chemotherapy (CHOP, CHOEP/EPOCH, BV-CH(E)P) is the standard first-line approach in this cohort PMID:37078708.
Sources
This page was processed by crosslinker on 2026-04-08. - PMID:24816253
This page was processed by wiki-cli on 2026-05-11.